Topics:

Exelixis/BMS to develop XL139, hedgehog pathway inhibitor

Exelixis/BMS to develop XL139, hedgehog pathway inhibitor

SOUTH SAN FRANCISCO, California—Exelixis, Inc. and Bristol-Myers Squibb Company will collaborate to co-develop and co-commercialize Exelixis' compound XL139, a small molecule inhibitor of the hedgehog pathway, in the United States. Hedgehog plays a critical role in regulating cell growth, proliferation, and differentiation, and is deregulated in a variety of cancers, making it a promising target for cancer therapies, Exelixis said.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.